To ask Her Majesty's Government what steps they will take to incorporate into clinical practice the treatment guidelines presented in “UK guidelines for the systemic treatment of renal cell carcinoma” published in the British Journal of Hospital Medicine (May 2009, vol. 70, no. 5). [HL4449]
There are currently no plans to incorporate these guidelines.
The National Institute for Health and Clinical Excellence (NICE) recently issued guidance on the use of sunitinib for the treatment of renal cell carcinoma. NICE is also currently appraising bevacizumab, sorafenib, temsirolimus, everolimus and pazopanib for the treatment of renal cell carcinoma.
NICE has also published two pieces of interventional procedures guidance on renal cancer, as well as its 2002 Improving Outcomes in Urological Cancers guidance, which addressed services and treatments for kidney cancer patients.